NuCana stock highlights a USD 7.0 million market cap

NuCana stock is attached to a USD 7.0 million market capitalization as of September 29, 2026, while the company remains a clinical-stage oncology developer. Its latest profile puts cash at USD 19.0 million and free cash flow at negative USD 5.0 million, creating a clear contrast between liquidity and ongoing operating burn.

Cash supports the development pipeline

NuCana describes itself as a clinical-stage biopharmaceutical company developing cancer medicines through its proprietary phosphoramidate technology. The platform is designed to improve the effectiveness and safety of anti-cancer treatments, placing research progress ahead of commercial revenue.

According to Stockray, the latest profile lists USD 19.0 million in cash and USD 5.0 million in negative free cash flow. The cash balance equals 271.43 percent of the stated USD 7.0 million market capitalization, a comparison that highlights the importance of financing discipline for a company still advancing clinical programs.

Revenue remains at the clinical stage

Stockray lists USD 0.0 million in revenue for 2026 Q2 and identifies the period as the latest quarterly profile. That figure fits NuCana's development-stage model, in which value depends on clinical milestones and potential partnering rather than product sales.

The same profile classifies NuCana in healthcare and biotechnology and identifies its NASDAQ listing. The company is developing oncology candidates supported by its ProTide platform, including programs aimed at solid tumors and hematological malignancies.

Market value stays tightly measured

NuCana's market capitalization stood at USD 7.0 million on September 29, 2026. Against that value, USD 19.0 million of cash represents 2.71 times the market capitalization, while negative USD 5.0 million of free cash flow shows the financial cost of continuing the pipeline.

More news and analyses on NuCana stock